^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Gallbladder Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    South Asian J Cancer
    Title:

    Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study

    Published date:
    12/14/2020
    Excerpt:
    ...patients of unresectable and/or metastatic GBC of age ≥18 years were enrolled. Four patients with ERBB2 amplification received trastuzumab and/or lapatinib, showed partial response, and maintained response beyond 12 weeks. One patient had mixed response, whereas two patients progressed on trastuzumab and lapatinib.
    DOI:
    10.1055/s-0040-1721180
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    HER2/neu-directed therapy for biliary tract cancer

    Published date:
    05/25/2020
    Excerpt:
    Nine patients with gallbladder cancer...had received HER2/neu-directed therapy (trastuzumab, lapatinib, or pertuzumab)…All other cases had HER2/neu amplification or overexpression....In all these cases, trastuzumab was associated with partial response (n = 4), stable disease (n = 3), or complete response (n = 1).
    DOI:
    10.1186/s13045-015-0155-z